Corifollitropin alfa

Thông tin thuốc gốc
Chỉ định và Liều dùng
Controlled ovarian stimulation
Adult: In combination with gonadotropin-releasing hormone (GnRH) antagonist for the development of multiple follicles as part of assisted reproductive technology (ART) programme: ≤36 years weighing ≤60 kg: 100 mcg as a single dose; >36 years weighing ≥50 kg: 150 mcg as a single dose; >60 kg, regardless of age: 150 mcg as a single dose. Initiate treatment during the early follicular phase of the menstrual cycle. Depending on the ovarian response, may give GnRH antagonist on stimulation day 5 or 6. Treatment may be continued with a recombinant FSH on day 8 until the criterion for triggering a final oocyte maturation (3 follicles ≥17 mm) is achieved. Generally, adequate follicular development is attained on average by 9th day of treatment (range: 6-18 days). When adequate follicular development is evident, give hCG on the same or next day to induce final oocyte maturation. In case of an excessive ovarian response, may consider therapy modification (refer to specific product guidelines).
Suy thận
Not recommended.
Chống chỉ định
Tumours of the ovary, breast, uterus, pituitary or hypothalamus; abnormal vaginal bleeding with unknown or undiagnosed cause; primary ovarian failure; ovarian cysts or enlarged ovaries; fibroid tumours of the uterus incompatible with pregnancy; malformations of the reproductive organs incompatible with pregnancy; history of ovarian hyperstimulation syndrome (OHSS); previous controlled ovarian stimulation cycle that resulted in >30 follicles ≥11 mm measured by ultrasound examination; basal antral follicle count >20; polycystic ovarian syndrome (PCOS). Pregnancy and lactation.
Thận trọng
Patient with risk factors for thromboembolic events (e.g. personal or family history, severe obesity, thrombophilia). Intended for single inj only; additional inj should not be given within the same treatment cycle. No additional FSH-containing product should be given prior to stimulation day 8. Not recommended for use with GnRH agonists and in renal impairment.
Tác dụng không mong muốn
Significant: Ovarian torsion, multiple pregnancies and births, ectopic pregnancies, congenital malformations, ovarian and other reproductive system neoplasms (benign and malignant), thromboembolic events.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation, abdominal distention.
General disorders and administration site conditions: Fatigue, inj site pain or haematoma, irritability.
Immune system disorders: Hypersensitivity reactions (local and generalised), including rash.
Injury, poisoning and procedural complications: Procedural pain.
Investigations: Increased ALT or AST.
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache, dizziness.
Pregnancy, puerperium and perinatal conditions: Spontaneous abortion.
Psychiatric disorders: Mood swings.
Reproductive system and breast disorders: Pelvic pain or discomfort, breast pain or tenderness, adnexa uteri pain, premature ovulation.
Vascular disorders: Hot flush.
Potentially Fatal: Ovarian hyperstimulation syndrome (OHSS).
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Prior to starting treatment: Assess the couple’s infertility; women should be evaluated for hypothyroidism, adrenocortical insufficiency, hyperprolactinaemia, pituitary or hypothalamic tumours, and other medical conditions that contraindicate pregnancy. Monitor follicular growth by transvaginal ultrasound and measurement of serum estradiol levels to determine adequate ovarian response and hCG timing. Evaluate for signs and symptoms of OHSS for at least 2 weeks after hCG administration.
Ảnh hưởng đến kết quả xét nghiệm
May cause a false-positive hCG pregnancy test if given during the ovarian stimulation portion of the ART cycle.
Tác dụng
Description: Corifollitropin alfa is a modified recombinant human FSH with a prolonged duration of activity. Its follicle stimulating activity can be sustained due to the addition of a carboxy-terminal peptide of the β-subunit of hCG to the β-chain of human FSH.
Duration: 7 days (sustained multiple follicular development activity).
Absorption: Bioavailability: 58% (range: 48-70%). Time to peak plasma concentration: 44 hours (range: 34-57 hours).
Distribution: Primarily distributed to ovaries and kidneys.
Excretion: Elimination half-life: 69 hours (range: 59-79 hours).
Bảo quản
Store between 2-8°C. May store at or below 25°C for up to 28 days. Do not freeze. Protect from light.
Phân loại MIMS
Hormon dinh dưỡng & các thuốc tổng hợp có liên quan
Phân loại ATC
G03GA09 - corifollitropin alfa ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
Tài liệu tham khảo
Anon. Corifollitropin Alfa. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 29/04/2022.

Buckingham R (ed). Corifollitropin Alfa. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 29/04/2022.

Elonva 150 mcg Solution for Injection (Organon Malaysia Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 29/04/2022.

Elonva 150 mcg Solution for Injection (Organon Pharma [UK] Limited). MHRA. Accessed 29/04/2022.

Organon (New Zealand) Limited. Elonva 100 mcg, 150 mcg Solution for Injection data sheet 16 August 2021. Medsafe. Accessed 29/04/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Corifollitropin alfa từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in